Università degli Studi del Molise, Dipartmento di Scienze per Salute, Via F De Sanctis, 86100 Campobasso, Italy.
Expert Opin Pharmacother. 2009 Dec;10(17):2859-70. doi: 10.1517/14656560903300129.
The second part of this two part review (please see Expert Opinion on Pharmacotherapy 10(16)) reports the characteristics of other antiglaucoma medications: systemic (acetazomide) and topical (dorzolamide and brinzolamide) carbonic anhydrase inhibitors, which suppress aqueous humour formation; and prostaglandin analogues (latanoprost and travoprost) and prostamides (bimatoprost), which raise aqueous humour outflow. The pharmacologic properties of each compound and its efficacy in the medical treatment of glaucoma, mainly the primary open-angle form, are discussed briefly, focusing on the clinical evidence supporting their use.
这篇由两部分组成的综述的第二部分(请参见《专家意见:药物疗法》第 10(16)期)报告了其他抗青光眼药物的特点:全身(乙酰唑胺)和局部(多佐胺和布林佐胺)碳酸酐酶抑制剂,抑制房水形成;前列腺素类似物(拉坦前列素和曲伏前列素)和前列胺(贝美前列素),增加房水流出。简要讨论了每种化合物的药理特性及其在青光眼(主要是原发性开角型青光眼)的药物治疗中的疗效,重点是支持其使用的临床证据。